Education
About Us
Working with TipRanks
Follow Us
CARGO Therapeutics, Inc. (CRGX)
NASDAQ:CRGX
CRGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.00 - $26.61
Previous CloseN/A
Volume19.28K
Average Volume (3M)795.58K
Market Cap
$193.42M
Enterprise Value$503.14M
Total Cash (Recent Filing)$64.38M
Total Debt (Recent Filing)$29.43M
Price to Earnings (P/E)―
Beta2.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding46,052,370
10 Day Avg. Volume1,043,351
30 Day Avg. Volume795,583
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)169.45
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.04
Forecast
1Y Price Target
$4.50Price Target Upside7.66% Upside
Rating ConsensusHold
Number of Analyst Covering9
---
CARGO Therapeutics, Inc. News
PremiumCompany Announcements
CARGO Therapeutics Announces Major Workforce Reduction
PremiumCompany Announcements
CARGO Therapeutics Highlights Progress in CAR T Therapy
---
Bulls Say, Bears Say
Bulls Say
Development InitiativesCargo plans to initiate enrollment for the Phase I study evaluating CRG-023, an autologous CAR-T cell therapy that expresses three fully human CAR molecules targeting CD19, CD20, and CD22.
Pipeline ProgressTri-specific CRG-023 continues to move forward with Phase I starting in Q2.
Bears Say
Clinical SetbacksCRGX announced the discontinuation of the Phase 2 FIRCE-1 study of Firi-cel due to disappointing efficacy and safety results, which rendered the product less competitive to pursue further.
Safety ConcernsSafety data showed 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome that were Grade 3 or higher, including both Grade 4 and 5.
Workforce ReductionCargo Therapeutics is implementing a workforce reduction of approximately 50% to preserve cash.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRGX FAQ
What was CARGO Therapeutics, Inc.’s price range in the past 12 months?
CARGO Therapeutics, Inc. lowest stock price was $3.00 and its highest was $26.61 in the past 12 months.
What is CARGO Therapeutics, Inc.’s market cap?
CARGO Therapeutics, Inc.’s market cap is $193.42M.
When is CARGO Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CARGO Therapeutics, Inc.’s earnings last quarter?
CARGO Therapeutics, Inc. released its earnings results on Aug 12, 2024. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$1.004 by -$0.016.
Is CARGO Therapeutics, Inc. overvalued?
According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued.
Does CARGO Therapeutics, Inc. pay dividends?
CARGO Therapeutics, Inc. does not currently pay dividends.
What is CARGO Therapeutics, Inc.’s EPS estimate?
CARGO Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CARGO Therapeutics, Inc. have?
CARGO Therapeutics, Inc. has 46,052,370 shares outstanding.
What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?
CARGO Therapeutics, Inc. reported an EPS of -$1.02 in its last earnings report, missing expectations of -$1.004. Following the earnings report the stock price went down -9.981%.
Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CRGX
---
CARGO Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.50 (7.66% Upside)
$4.50 (7.66% Upside)
Blogger Sentiment
Bullish
CRGX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 33.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.78%
12-Months-Change
Fundamentals
Return on Equity
-43.76%
Trailing 12-Months
Asset Growth
-8.60%
Trailing 12-Months
Company Description
CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
---
CRGX Stock 12 Month Forecast
Average Price Target
$4.50
▲(7.66% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering CRGX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-52.34%
downgraded a sell rating 2 months ago
Copying Brian Cheng's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -52.34% per trade.
---